Market revenue in 2023 | USD 29.5 million |
Market revenue in 2030 | USD 42.7 million |
Growth rate | 5.4% (CAGR from 2023 to 2030) |
Largest segment | Cardiopulmonary perfusion system |
Fastest growing segment | Cardiopulmonary Perfusion System |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cardiopulmonary Perfusion System, Cell Perfusion System, Ex-Vivo Organ Perfusion System |
Key market players worldwide | Getinge AB ADR, Medtronic PLC, LivaNova PLC, Terumo Corp, Nipro Corp, Fresenius Medical Care AG, Repligen Corp, Spectrum Brands Holdings Inc, Merck KGaA, Xvivo Perfusion AB |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to perfusion systems market will help companies and investors design strategic landscapes.
Cardiopulmonary perfusion system was the largest segment with a revenue share of 44.75% in 2023. Horizon Databook has segmented the Australia perfusion systems market based on cardiopulmonary perfusion system, cell perfusion system, ex-vivo organ perfusion system covering the revenue growth of each sub-segment from 2018 to 2030.
The rising prevalence of chronic respiratory diseases is a significant driver of the perfusion system market in Australia. According to the Australian Bureau of Statistics, the prevalence of COPD has been stable, increasing slightly from 2.4% in 2011 to 2012 to 2.5% in 2022.
More patients are seeking treatment for respiratory failure, increasing the demand for effective perfusion systems. These systems are also crucial for expediting recovery during heart and lung surgeries. In addition, their growing popularity is due to reduced patient trauma, shorter hospital stays, and quicker recovery time.
These factors are expected to enhance the adoption of perfusion systems in Australia’s healthcare sector. According to the Australian Institute of Health and Welfare, in 2023, respiratory conditions accounted for 7.2% of the total disease burden (measured in Disability-adjusted Life Years or DALYs), 8.5% of the nonfatal burden (Years Lived With Disability or YLDs), and 5.8% of the fatal burden (Years of Life Lost or YLLs) in Australia.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia perfusion systems market , including forecasts for subscribers. This country databook contains high-level insights into Australia perfusion systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account